3Wu Y,Carlsson LE,Liu T,et al.Assessment of proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in expermental models of torsades de pointes.J Cardiovas Electrophysiol,2005,7:1-7.
6Demolis JE,Funck-Brentano CH,Ropers JA,et al.Influence of dofetiliide on QT interval duration and dispersion at various heart rates during exercise in humans.Circulation,1996,94:1592-1599.
7Le CF,Funck-Brentano C,Morell T,et al.Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.Clin Pharmacol Ther,1995,57:533-542.
8Duff HJ,Feng ZP,Sheldon RS,et al.High and low affinity sites for dofetilide binding to guinea pig myocytes.Circ Res,1995,77:718-725.
1[1]LYNCH JJ, BASKIN EP, NUTT EM, et al. Comparison of binding to rapidly activating delayed rectifier K+ channel, Ikr and effects on myocardial refractoriness for class Ⅲ antiarrhythmic agents [J]. J Cardiovasc Pharmacol, 1995, 25(2):336-340.
3[3]FALK RH, POLLAK A, SINGH SN, et al. Intravenous dofetilide, a class Ⅲ antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter [J]. J Am Coll Cardiol, 1997, 29(2):385-390.
4[4]DEMOLIS JL, FUNCK-BRENTANO C, ROPERS J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans [J]. Circulation, 1996, 94(7):1592-1599.
5[5]THAM TCK, MACLENNAN BA, BURKE MT, et al. Pharmacodynamics and pharmacokinetics of the class Ⅲ antiarrhythmic agent dofetilide (UK-68798) in humans [J]. J Cardiovasc Pharmacol, 1993, 21(3):507-512.
6[6]GJINI V, SCHREIECK J, KORTH M, et al. Frequency dependence in the action of the class Ⅲ antiarrhythmic drug dofetilide is modulated by altering L-type calcium current and digitalis glucoside [J]. J Cardiovasc Pharmacol, 1998, 31(1): 95-100.
7[7]ROUSSEAU MF, MASSART PE, De KOCK M, et al. Cardiac function and QT dispersion during Ⅳ antiarrhythmic dosing in heart failure patients: superiority of dofetilide over amiodarone [J]. Circulation, 1996, 94(8 Suppl l): 245.
8[8]DECARA JM, POLLAR A, DUBREY S, et al. Positive atrial inotropic effects of dofetilide following cardioversion of atrial fibrillation [J]. J Am Coll Cardiol, 1998, 31 (2 Suppl A): 432A-433A.
9[9]TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction [J]. N Engl J Med, 1999, 341(12):857-865.
10[10]MCCLELLAN KJ, MARKHAM A. Dofetilide: a review of its use in atrial fibrillation and atrial flutter [J]. 1999, 58(6):1043-1059.
